Larry Norton, MD. Photo by Juliana Thomas.

A recent Washington Post article about advances in cancer treatment features MSK.

The article begins by sharing the experiences of a patient, Kelly Spill, who enrolled in an MSK clinical trial using immunotherapy to treat her rectal cancer. She and the other 17 trial participants all had a complete clinical response from the treatment. Ms. Spill has been cancer-free for nearly three years.

For many, cancer is now serious but treatable. MSK’s Dr. Larry Norton attributes this to improvements in prevention, screening, diagnostics, and treatment. He makes special note of the impact immunotherapies have had on many patient outcomes.

These positive changes make the need for survivorship care even more critical. Learn more about MSK’s survivorship and follow-up care programs.